Blood–brain barrier permeability and tPA-mediated neurotoxicity

Tissue type plasminogen activator (tPA) can induce neuronal apoptosis, disrupt the blood-brain barrier (BBB), and promote dilation of the cerebral vasculature. The timing, sequence and contributions of these and other deleterious effects of tPA and their contribution to post-ischemic brain damage after stroke, have not been fully elucidated. To dissociate the effects of tPA on BBB permeability, cerebral vasodilation and protease-dependent pathways, we developed several tPA mutants and PAI-1 derived peptides constructed by computerized homology modeling of tPA. Our data show that intravenous administration of human tPA to rats increases BBB permeability through a non-catalytic process that is associated with reversible neurotoxicity, brain damage, mortality and contributes significantly to its brief therapeutic window. Furthermore, our data show that inhibiting the effect of tPA on BBB function without affecting its catalytic activity, improves outcome and significantly extends its therapeutic window in mechanical as well as in thromboembolic models of stroke.

[1]  W. Armstead,et al.  Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. , 2005, Brain research. Developmental brain research.

[2]  K. Bdeir,et al.  α-Defensin: Link between inflammation and atherosclerosis , 2007 .

[3]  K. Bdeir,et al.  In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. , 2004, Blood.

[4]  D. Cines,et al.  Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. , 2005, Blood.

[5]  D. Lawrence,et al.  Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.

[6]  Alain Buisson,et al.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.

[7]  D. Choi,et al.  Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.

[8]  P. Kochanek,et al.  Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. , 1998, Acta neurochirurgica. Supplement.

[9]  A. Higazi,et al.  Identification of an Inhibitor of Tissue-type Plasminogen Activator-mediated Fibrinolysis in Human Neutrophils , 1995, The Journal of Biological Chemistry.

[10]  M. Chopp,et al.  Intravenous Administration of Human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats , 2001, Stroke.

[11]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[12]  D. Cines,et al.  LRP and αvβ3 mediate tPA activation of smooth muscle cells , 2006 .

[13]  Y. Katayama,et al.  Hemorrhagic Transformation After Fibrinolysis With Tissue Plasminogen Activator: Evaluation of Role of Hypertension With Rat Thromboembolic Stroke Model , 2001, Stroke.

[14]  E. Goldsmith,et al.  Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.

[15]  R. Huber,et al.  Lysine 156 promotes the anomalous proenzyme activity of tPA: X‐ray crystal structure of single‐chain human tPA , 1997, The EMBO journal.

[16]  P. Carmeliet,et al.  Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. , 1999, Circulation.

[17]  M. Llinás,et al.  Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. , 1991, Journal of molecular biology.

[18]  J. Geiger,et al.  Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease , 2008, Journal of Neuroinflammation.

[19]  Roman A Laskowski,et al.  Structural quality assurance. , 2003, Methods of biochemical analysis.

[20]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[21]  A. Al-Mehdi,et al.  Urokinase‐derived peptides regulate vascular smooth muscle contraction in vitro and in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  J L Sussman,et al.  Protein Data Bank archives of three-dimensional macromolecular structures. , 1997, Methods in enzymology.

[23]  B. Winblad,et al.  Blood-brain barrier in Alzheimer dementia and in non-demented elderly , 1987, Acta Neuropathologica.

[25]  E. Goldsmith,et al.  Restoration of serine protease-inhibitor interaction by protein engineering. , 1990, The Journal of biological chemistry.

[26]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[27]  M. Sabel,et al.  Locoregional opening of the rodent blood–brain barrier for paclitaxel using Nd:YAG laser‐induced thermo therapy: A new concept of adjuvant glioma therapy? , 2003, Lasers in surgery and medicine.

[28]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.

[29]  T. Coleman,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Neuroserpin reduces cerebral infarct volume and protects neurons from , 2022 .

[30]  Douglas H. Smith,et al.  Neutralizing the neurotoxic effects of exogenous and endogenous tPA , 2006, Nature Neuroscience.

[31]  E. Goldsmith,et al.  Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition , 1995, Nature Structural Biology.

[32]  E. Goldsmith,et al.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ulf Eriksson,et al.  Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.

[34]  D. Cines,et al.  Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. , 1998, Blood.

[35]  C. Siao,et al.  Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma , 2001, Neuroreport.

[36]  C. Rosen,et al.  Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion , 2009, Brain Research.

[37]  S. Papson,et al.  “Model” , 1981 .